Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 972,378 | 736,578 | -257,998 | -227,318 | -151,529 |
| Depreciation Amortization | 10,219 | 4,939 | 20,021 | 15,046 | 10,050 |
| Accounts receivable | -70,983 | -42,576 | 17,636 | 29,384 | 56,813 |
| Accounts payable and accrued liabilities | 10,068 | -24,638 | -11,736 | -38,677 | -29,013 |
| Other Working Capital | -27,723 | -78,211 | 80,284 | 36,356 | 81,731 |
| Other Operating Activity | -575,424 | -605,130 | 212,771 | 162,414 | 7,366 |
| Operating Cash Flow | $318,535 | $-9,037 | $60,979 | $-22,795 | $-24,582 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -12,729 | -9,026 | -9,600 | -5,954 | -5,723 |
| Other Investing Activity | 1,559 | 1,122 | 0 | 0 | 0 |
| Investing Cash Flow | $-11,170 | $-7,904 | $-9,600 | $-5,954 | $-5,723 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -19,440 | -10,042 | -24,843 | -17,678 | -9,709 |
| Common Stock Issued | 58,235 | 37,014 | 98,520 | 83,842 | 29,858 |
| Common Stock Repurchased | -120,237 | -60,693 | -19,682 | -20,334 | -19,748 |
| Other Financing Activity | -15,006 | -9,388 | -12,894 | -13,321 | -12,937 |
| Financing Cash Flow | $-96,448 | $-43,109 | $41,102 | $32,508 | $-12,536 |
| Exchange Rate Effect | 17,228 | 9,464 | -28,559 | -27,664 | -31,512 |
| Beginning Cash Position | 716,271 | 721,014 | 633,067 | 654,050 | 635,193 |
| End Cash Position | 944,415 | 670,429 | 696,989 | 630,145 | 560,841 |
| Net Cash Flow | $228,144 | $-50,586 | $63,922 | $-23,905 | $-74,352 |
| Free Cash Flow | |||||
| Operating Cash Flow | 318,535 | -9,037 | 60,979 | -22,795 | -24,582 |
| Capital Expenditure | -12,729 | -9,026 | -9,600 | -5,954 | -5,723 |
| Free Cash Flow | 305,805 | -18,063 | 51,379 | -28,749 | -30,304 |